

3 dendritic cells take up and present said antigen,] have been cryopreserved prior to exposure in
4 vitro to the prostate antigen, wherein said human dendritic cells retain the ability to take up and
5 present the antigen.

Please insert the following new claims:

1 -- 31.(New) The composition according to claim 23 comprising at least 20
2 fold more dendritic cells competent to and enabled to activate prostate antigen specific T cells
3 compared to the number of dendritic cells directly isolated from peripheral blood. --

1 --.32.(New) The composition according to claim 23, wherein the human
2 dendritic cells are immature dendritic cells.

1 -- 33.(New) The composition according to claim 23, wherein the T cells are
2 CD4⁺. --

1 -- 34.(New) The composition according to claim 23, wherein the T cells are
2 CD8⁺. --

1 -- 35.(New) The composition according to claim 23, wherein the dendritic
2 cells are isolated from a prostate cancer patient. --

1 -- 36.(New) The composition according to claim 23, wherein the dendritic
2 cells are isolated from a normal individual. --

1 -- 37.(New) The composition according to claim 36, wherein the dendritic
2 cells are HLA-matched for a recipient. --

REMARKS

Claims 23, 24, 26 and 28-30 have been examined. By this amendment, claims 23 and 28 have been amended to further distinguish the present invention. In addition Applicants have added claims 31 through 37 to explicitly recite particular aspects of the present invention. Support for the new claims can be found throughout the specification.